ALK-话题@MedSci - williamhill asia

#ALK#

2篇内容 | 1701人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2217275, encodeId=54c7221e27527, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=0de5290588c' target=_blank style='color:#2F92EE;'>#免疫检查点抑制剂#</a> <a href='/topic/show?id=51c91669428' target=_blank style='color:#2F92EE;'>#SRS#</a>, objectTitle=JCO：EGFR和ALK驱动型NSCLC脑转移：TKIs联合SRS治疗的优势, objectType=article, longId=836556, objectId=82d1836556ec, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240728/1722134116965_6145188.png, objectUrl=/article/show_article.do?id=82d1836556ec, replyNumber=0, likeNumber=11, createdTime=2024-07-28, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=82d1836556ec, moduleTitle=JCO：EGFR和ALK驱动型NSCLC脑转移：TKIs联合SRS治疗的优势, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=82d1836556ec)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205620, encodeId=441d2205620d2, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a> <a href='/topic/show?id=2ef511465684' target=_blank style='color:#2F92EE;'>#EML4#</a>, objectTitle=Drug Resist Updat：联合使用ALK抑制剂和SRC抑制剂有望延缓肺癌细胞产生抗药性, objectType=article, longId=826620, objectId=7ed782662090, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240519/1716117893572_2185383.png, objectUrl=/article/show_article.do?id=7ed782662090, replyNumber=0, likeNumber=23, createdTime=2024-05-20, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2203763, encodeId=49302203e635b, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a>, objectTitle=确诊肺癌且EGFR或ALK基因突变，什么时候用靶向药治疗效果好?, objectType=article, longId=825058, objectId=dc2a82505840, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240509/1715264765962_5579292.jpg, objectUrl=/article/show_article.do?id=dc2a82505840, replyNumber=0, likeNumber=49, createdTime=2024-05-09, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=dc2a82505840, moduleTitle=确诊肺癌且EGFR或ALK基因突变，什么时候用靶向药治疗效果好?, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dc2a82505840)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2202225, encodeId=7173220222545, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a>, objectTitle=延缓ALK肺癌的靶向药耐药，最近有了新的组合用药方案！, objectType=article, longId=823916, objectId=c9c3823916ff, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=c9c3823916ff, replyNumber=0, likeNumber=0, createdTime=2024-05-07, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c9c3823916ff, moduleTitle=延缓ALK肺癌的靶向药耐药，最近有了新的组合用药方案！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c9c3823916ff)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2186196, encodeId=9d4e2186196d0, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a>, objectTitle=2023 ESMO｜李茵茵教授：肺癌ALK领域新进展, objectType=article, longId=812547, objectId=1fca81254e29, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668017232524_4754896.png, objectUrl=/article/show_article.do?id=1fca81254e29, replyNumber=0, likeNumber=56, createdTime=2024-02-06, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1fca81254e29, moduleTitle=2023 ESMO｜李茵茵教授：肺癌ALK领域新进展, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1fca81254e29)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183024, encodeId=465821830245b, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=6bf49e844e9' target=_blank style='color:#2F92EE;'>#阿替利珠单抗#</a>, objectTitle=JCO：阿替利珠单抗联合贝伐珠单抗联合化疗治疗 EGFR 或 ALK 突变非小细胞肺癌患者的 III 期随机研究 , objectType=article, longId=810273, objectId=b8da8102e328, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240120/1705761668295_6145188.png, objectUrl=/article/show_article.do?id=b8da8102e328, replyNumber=0, likeNumber=45, createdTime=2024-01-21, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b8da8102e328, moduleTitle=JCO：阿替利珠单抗联合贝伐珠单抗联合化疗治疗 EGFR 或 ALK 突变非小细胞肺癌患者的 III 期随机研究 , moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b8da8102e328)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1222738, encodeId=29da1222e38dd, content=<a href='/topic/show?id=514533410b1' target=_blank style='color:#2F92EE;'>#劳拉替尼#</a>一线治疗较<a href='/topic/show?id=1dcf288e1cd' target=_blank style='color:#2F92EE;'>#克唑替尼#</a>改善<a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a>阳性晚期<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>有或无脑转移患者的PFS，不用说劳拉是第二代，肯定更强。当然，第三代也在开发中。, objectTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, objectType=article, longId=727788, objectId=2cfae27788c8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220524/1653394222972_1611618.jpeg, objectUrl=/article/show_article.do?id=2cfae27788c8, replyNumber=0, likeNumber=157, createdTime=2022-05-27, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cfae27788c8, moduleTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2cfae27788c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=900808, encodeId=b980900808f3, content=<a href='/topic/show?id=514533410b1' target=_blank style='color:#2F92EE;'>#劳拉替尼#</a>不愧是神药级！对于<a href='/topic/show?id=332e230890' target=_blank style='color:#2F92EE;'>#ALK#</a>融合基因的<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>是神药！Lorbrena治疗组在12个月时无疾病进展的存活患者占78%, objectTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, objectType=article, longId=203570, objectId=632d2035e081, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201120/1605839635333_5085975.png, objectUrl=/article/show_article.do?id=632d2035e081, replyNumber=0, likeNumber=228, createdTime=2020-11-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632d2035e081, moduleTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=632d2035e081)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

ALK

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#NSCLC# #ALK# #EGFR# #免疫检查点抑制剂# #SRS#

JCO：EGFR和ALK驱动型NSCLC脑转移：TKIs联合SRS治疗的优势

2024-07-28发表于上海

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #ALK# #EML4#

2024-05-20发表于上海

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#肺癌# #ALK# #EGFR#

确诊肺癌且EGFR或ALK基因突变，什么时候用靶向药治疗效果好?

2024-05-09发表于上海

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#肺癌# #ALK#

延缓ALK肺癌的靶向药耐药，最近有了新的组合用药方案！

2024-05-07发表于上海

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#肺癌# #ALK#

2023 ESMO｜李茵茵教授：肺癌ALK领域新进展

2024-02-06发表于陕西省

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #ALK# #EGFR# #阿替利珠单抗#

JCO：阿替利珠单抗联合贝伐珠单抗联合化疗治疗 EGFR 或 ALK 突变非小细胞肺癌患者的 III 期随机研究

2024-01-21发表于上海

清风徐来2022 (审核中...)

前往app查看评论内容

#劳拉替尼#一线治疗较#克唑替尼#改善#ALK#阳性晚期#NSCLC#有或无脑转移患者的PFS，不用说劳拉是第二代，肯定更强。当然，第三代也在开发中。

J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS

2022-05-27

lovetcm (审核中...)

前往app查看评论内容

#劳拉替尼#不愧是神药级！对于#ALK#融合基因的#NSCLC#是神药！Lorbrena治疗组在12个月时无疾病进展的存活患者占78%

NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼

2020-11-20

科室
- - 订阅+
  - 更多科室
工具
服务